Chemed (CHE) has expanded its Roto-Rooter footprint, with the subsidiary buying its largest independent franchise in California for US$60.6 million, covering territories that serve roughly 11 million people.
Recent trading has been choppy for Chemed, with the share price down 8.13% over the past month, yet still up 17.19% on a year to date basis and delivering a 10.0% total shareholder return over the past year. This suggests momentum has cooled but not reversed.
Scan how Chemed’s acquisition compares with other businesses expanding through targeted deals by reviewing the hand picked 16 high quality undiscovered gems that are also using focused growth to build scale.
Chemed now controls a larger Roto-Rooter operation after paying roughly 1.1x to 1.2x the franchise’s recent revenue. The real puzzle is whether that combination of deal terms and share pullback argues for patience or for acting now.
Most Popular Narrative: 16% Undervalued
Chemed’s most followed narrative places fair value at $590, above the recent close of $496.62. This frames the Roto-Rooter deal inside a wider earnings and cash flow story driven by both hospice and plumbing operations.
VITAS is repositioning its admission mix away from an unusually high share of short-stay, hospital based patients toward a more balanced pattern that historically supports higher average daily census, which could feed through to steadier revenue growth and stronger EBITDA margins over time.
See why 2 investors see Chemed as 16% undervalued.
Result: Fair Value of $590 (UNDERVALUED)
Still, this bullish Chemed story leans heavily on VITAS successfully shifting its patient mix and on Roto-Rooter containing digital lead costs that could otherwise squeeze profitability.
Find out about the key risks to this Chemed narrative.
Next Steps
Sentiment around Chemed is mixed, with both concerns and bright spots on the table, so move quickly, review the data, and weigh the 3 key rewards and 1 important warning sign
Looking for more Chemed sized investment ideas?
Do not stop at Chemed. Use powerful filters to uncover new opportunities, compare quality across sectors, and keep your watchlist packed with fresh ideas that others might miss.
- Target quality at a discount by scanning a curated set of potential bargains through the 29 high quality undervalued stocks.
- Prioritise resilience by reviewing companies with stronger finances using the list of solid balance sheet and fundamentals (23 results).
- Hunt for under the radar potential by checking the 9 elite penny stocks with strong financials before the crowd catches on.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com